Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Other Accumulated Expenses (2023 - 2026)

ArriVent BioPharma has reported Other Accumulated Expenses over the past 4 years, most recently at $39000.0 for Q1 2026.

  • Quarterly results put Other Accumulated Expenses at $39000.0 for Q1 2026, down 75.78% from a year ago — trailing twelve months through Mar 2026 was $39000.0 (down 75.78% YoY), and the annual figure for FY2025 was $18000.0, down 73.13%.
  • Other Accumulated Expenses reached $39000.0 in Q1 2026 per AVBP's latest filing, up from $18000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $161000.0 in Q1 2025 and bottomed at $18000.0 in Q4 2025.
  • Median Other Accumulated Expenses over the past 4 years was $86000.0 (2024), compared with a mean of $90200.0.
  • The largest annual shift saw Other Accumulated Expenses surged 335.14% in 2025 before it plummeted 75.78% in 2026.
  • Over 4 years, Other Accumulated Expenses stood at $62000.0 in 2023, then increased by 8.06% to $67000.0 in 2024, then crashed by 73.13% to $18000.0 in 2025, then skyrocketed by 116.67% to $39000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for AVBP at $39000.0 in Q1 2026, $18000.0 in Q4 2025, and $105000.0 in Q3 2025.